A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

Inclusion Criteria Concurrent Medication: Allowed: * Aerosolized pentamidine. * Acute and intermittent therapy with mycostatin and mycelex. * Isoniazid, if no alternative therapy is available. Allowed for up to 2 weeks: * Acyclovir for Herpes infection (withhold didanosine during therapy). * Acute therapy with fluconazole or ketoconazole. Allowed but preferably not on a continuous basis for \> 72 hours: * Acetaminophen. * Ibuprofen. * Nonsteroidal antiinflammatory agents. Patients must be: * HIV antibody positive. * Asymptomatic or have persistent generalized lymphadenopathy. * Diagnosed with one of the listed coagulopathies. * OR Sexual partner of someone with the above criteria. Allowed: * Basal cell carcinoma or in situ carcinoma of the cervix. NOTE: * As of January, 1991 full accrual of patients with prior AZT use has been reached - NOW ACCRUING ONLY THOSE WITH NO PRIOR AZT USE. Hemophilia restriction has been lifted. Prior Medication: Allowed: * Zidovudine (AZT) for a total of = or \< 13 months. NOTE: * As of January, 1991 accrual of these patients was reached, NOW ONLY PATIENTS WITH NO PRIOR AZT. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Unexplained temperature \> 38 degrees C for more than 5 consecutive days or on more than 10 days in any 30-day period in the 2 years prior to study entry. * Unexplained diarrhea defined as at least 3 liquid stools/day persisting more than 7 days wit…